Neuspera Medical Inc.

Neuspera Medical Inc. (#LSIAlumni) closed a $23M Series D funding round led by Vertex Ventures HC and Treo Ventures. The round also had participation from Action Potential Venture Capital, Windham Venture Partners, Olympus Corporation Innovation Ventures, and another strategic investor. This round will fund the company through expected FDA premarket approval of the Neuspera System. The system is a discreet, minimally invasive, ultra-miniaturized implant designed to provide patients personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB). It's the least invasive sacral neuromodulation device and includes an ultra-miniaturized pulse generator attached to an electrode array. The Neuspera System has FDA clearance for treating chronic pain of peripheral nerve origin and is currently an investigational device for treating UUI, a symptom associated with OAB. Congratulations to LSI Alumni, Steffen Hovard and the entire Neuspera Medical team on this major milestone! We look forward to following along your journey. Watch Steffen’s full LSI USA ‘24 presentation to learn more about Neuspera Medical - Available on our website and YouTube channel.

We’re pleased to announce the closing of our $23 million Series D funding round, led by Vertex Ventures HC and Treo Ventures with participation by Action Potential Venture Capital, Windham Capital Partners, Olympus Corporation Innovation Ventures and another strategic investor.     We’re extremely grateful to this group of investors for their partnership and support which will provide funding through expected U.S. Food and Drug Association premarket approval of the Neuspera System, the discreet, minimally invasive, ultra-miniaturized implant designed to provide patients personal control and relief from urinary urge incontinence a symptom of overactive bladder.    More details are available at in the press release, here: https://lnkd.in/de_f9u2F.    #OAB #urology #neuromodulation #medtech

We’re grateful to Paradromics Inc. Founder and CEO Matt Angle, Ph.D. for having our Founder and CTO Alexander Yeh, Ph.D., along with Motif Neurotech Founder and CEO Jacob Robinson, Ph.D. and Resonant Link Co-Founder and CEO Grayson Z., PhD on the latest episode of the Neurotech Pub podcast.     Check out this “stimulating” deep-dive conversation into how our respective technologies are shifting the paradigm for how patients with underlying neurological conditions may receive care in the not-too-distant future: https://lnkd.in/gdDjG_6e.     #Neuspera #OAB #urology #neuromodulation #medtech #medicaldevice #tech #digitalhealth

Attention jobseekers! Neuspera is currently hiring for two positions: Controller and Supply Chain Director. To learn more about each of these roles and how to apply, check out the links below.   Controller position: https://lnkd.in/g-UaX_n2   Supply Chain Director position: https://lnkd.in/gJb84qNQ   #HiringNow #jobs #NowHiring #CareerOpportunities #JobOpening #Neuspera #neuromodulation #medtech #medicaldevice #finance #urology 

We are honored that after a competitive selection process with a five percent acceptance rate, we are among the 65 companies included in the 2024 MedTech Innovator Accelerator Cohort! We’re excited about the positive impact this will have as we prepare to launch our minimally invasive, ultra-miniaturized Neuspera Sacral Neuromodulation system designed to treat OAB, while eliminating the need for an implanted battery.   MedTech Innovator is the world’s largest accelerator of medical technology companies. Its flagship four-month Accelerator program has become the gold standard, thanks to the organization's industry-leading track record of identifying and refining the most innovative medtech and digital health startups in the world.   Congratulations to the rest of this year’s cohort! More about the program and other participating startups can be found here: https://lnkd.in/geCyuGs8.   Note: The Neuspera Sacral Neuromodulation System is limited to investigational use only.    #Neuspera #OAB #urology #neuromodulation #medtech #medicaldevice #tech #digitalhealth #mti #cohort #strategics

We’re encouraged by the recently announced new 2024 AUA/SUFU guideline. Read on for an excerpt of our full statement on these guidelines from our Chief Medical Officer, Dr. Steven Siegel. The full statement can be found on our website: https://lnkd.in/grB-3ePa.   The guideline on the Diagnosis and Treatment of Idiopathic OAB promotes a shared decision-making process between the patient and physician that weighs the patient’s comorbidities along with expressed values, preferences, and treatment goals in order to help them make an informed decision regarding treatment. Neuspera believes that because of this shared decision making with their caregiver, it will facilitate OAB patients’ access to their most desired and appropriate option. This completely revised guideline recognizes the difficulties and drawbacks with previous tiered therapies including behavioral interventions and medications, noting that patients may have been worn-out by them before having the opportunity to try more potentially attractive and effective alternatives. Options including intradetrusor botulinum toxin injection, sacral neuromodulation, and PTNM, previously labeled as “Third Line Therapies,” are now classified as “Minimally Invasive Therapies.” Sacral neuromodulation is recognized as the “gold standard” neuromodulation therapy for OAB. The Neuspera Sacral Neuromodulation system is designed to be minimally invasive, ultra-miniaturized and to eliminate the need for an implanted battery, which we believe will be an important option for patients in their shared decision-making process.

We are looking forward to presenting the Neuspera Medical journey update at the Jefferies Global Healthcare Conference in New York early June. Happy to find time for additional 1x1's as long as the agenda allows. #JefferiesHealthcare #Neuromodulation #OAB #Innovation

We are looking forward to presenting the Neuspera Medical journey update at the Jefferies Global Healthcare Conference in New York early June. Happy to find time for additional 1x1's as long as the agenda allows. #JefferiesHealthcare #Neuromodulation #OAB #Innovation

The Neuspera team had an excellent time in San Antonio at the American Urological Association Annual Meeting. Thank you to all of the physicians and industry partners who took the time to meet with us as we continue moving forward with bringing the Neuspera Sacral Neuromodulation System -- a discreet, ultra-miniaturized, minimally invasive therapy that is designed to provide patients with relief from their overactive bladder (OAB) symptoms – to the market! *Investigational use only #AUA24 #OAB #urology #incontinence #neuromodulation

The Neuspera team is gearing up for this year’s American Urological Association Annual Meeting in San Antonio May 3-6! We are looking forward to continuing some ongoing market research projects and meeting with physicians and industry partners – please reach out via email or send a LinkedIn message to set up a meeting.   #AUA2024 #OAB #urology #incontinence #neuromodulation